Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Concentration effect relationship of CYP3A inhibition by ritonavir in humans.

Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G.

Eur J Clin Pharmacol. 2013 Oct;69(10):1795-800. doi: 10.1007/s00228-013-1530-8. Epub 2013 Jun 9.

PMID:
23748748
2.

Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.

Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G.

Clin Pharmacol Ther. 2010 Feb;87(2):191-6. doi: 10.1038/clpt.2009.206. Epub 2009 Nov 18.

PMID:
19924124
3.

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.

Mathias AA, West S, Hui J, Kearney BP.

Clin Pharmacol Ther. 2009 Jan;85(1):64-70. doi: 10.1038/clpt.2008.168. Epub 2008 Sep 24.

PMID:
18815591
4.

Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.

Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G.

Clin Pharmacol Ther. 2011 Nov;90(5):666-73. doi: 10.1038/clpt.2011.164. Epub 2011 Sep 21.

PMID:
21937987
5.

Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.

Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM.

Clin Drug Investig. 2008;28(8):479-85.

PMID:
18598093
6.

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schömig E, Burger DM, Fätkenheuer G, Jetter A.

Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.

PMID:
18183034
7.

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, Court MH.

Br J Clin Pharmacol. 2009 Dec;68(6):920-7. doi: 10.1111/j.1365-2125.2009.03545.x.

8.

Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.

Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E.

Pharmacotherapy. 2009 Oct;29(10):1175-81. doi: 10.1592/phco.29.10.1175.

PMID:
19792991
9.

Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR.

Curr Med Res Opin. 2008 Feb;24(2):591-9. doi: 10.1185/030079908X260871 .

PMID:
18205997
10.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
11.

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI.

J Clin Pharmacol. 2003 Apr;43(4):414-22.

PMID:
12723462
12.

Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.

Tomaru A, Takeda-Morishita M, Banba H, Takayama K.

Drug Metab Pharmacokinet. 2013;28(2):144-52. Epub 2012 Sep 11.

13.
14.

Alprazolam-ritonavir interaction: implications for product labeling.

Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI.

Clin Pharmacol Ther. 2000 Apr;67(4):335-41.

PMID:
10801241
15.

Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.

Ieiri I, Tsunemitsu S, Maeda K, Ando Y, Izumi N, Kimura M, Yamane N, Okuzono T, Morishita M, Kotani N, Kanda E, Deguchi M, Matsuguma K, Matsuki S, Hirota T, Irie S, Kusuhara H, Sugiyama Y.

J Clin Pharmacol. 2013 Jun;53(6):654-61. doi: 10.1002/jcph.62. Epub 2013 Feb 4.

PMID:
23381882
16.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.

Morcos PN, Chang L, Kulkarni R, Giraudon M, Shulman N, Brennan BJ, Smith PF, Tran JQ.

Eur J Clin Pharmacol. 2013 Nov;69(11):1939-49. doi: 10.1007/s00228-013-1556-y. Epub 2013 Jul 20.

PMID:
23872824
17.
18.

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Clin Pharmacol Ther. 2013 Jun;93(6):564-71. doi: 10.1038/clpt.2013.27. Epub 2013 Feb 8.

PMID:
23511711
19.

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C.

Clin Pharmacol Ther. 2008 Oct;84(4):506-12.

20.

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD.

Drug Metab Dispos. 2011 Jun;39(6):1070-8. doi: 10.1124/dmd.110.037523. Epub 2011 Mar 15.

Supplemental Content

Support Center